Literature DB >> 2378463

Antigenic structure of Coxiella burnetii. A comparison of lipopolysaccharide and protein antigens as vaccines against Q fever.

J C Williams1, T A Hoover, D M Waag, N Banerjee-Bhatnagar, C R Bolt, G H Scott.   

Abstract

The antigenic structure of Coxiella burnetii is being investigated by identifying both external and internal cellular epitopes of the morphologic cell types. Both the phase I lipopolysaccharide (LPSI) and several surface proteins are candidates for the development of subunit multivalent vaccines. The protective efficacy of purified LPSI was demonstrated in A/J mice. The purified LPSI preparations contained residual peptides detected by amino acid analysis. Therefore, the protection afforded by LPSI may be, in part, due to the presence of peptides. The purification of proteins free of LPSI must be accomplished before the protective efficacy of proteins or peptides can be established. We have identified three proteins that are both antigenic and immunogenic, as indicated by either enzyme immunoassay, radioimmunoprecipitation, immunoblot assay, or lymphocyte transformation. A 62-kDa protein antigen encoded by the htpB gene of C. burnetii was analyzed for immunogenicity. The purified protein antigen was immunogenic, as it elicited specific antibodies and performed as recall antigen in lymphocyte stimulation assays. The antigen was not detected on the surface of phase I cells but was highly represented on the surface of phase II cells. Therefore, the protein may not be a good candidate for vaccine development. The diagnostic utility of the 62-kDa protein antigen lies in the fact that convalescent and chronic Q fever sera from human patients reacted with the antigen, whereas acute sera did not. Although the 62-kDa protein is a "common antigen," specific peptide-based diagnostic reagents may be useful in the detection of Q fever disease progression. A major surface protein (P1) of roughly 29.5 kDa was purified from the phase I Nine Mile (clone 7) strain. No LPSI was detected in the P1 preparation by three different LPSI monoclonal antibodies. Monoclonal antibodies prepared against P1 were effective in localizing the protein on the cell surface, in the cell wall, and associated with the peptidoglycan of large cells of C. burnetii. Small, pressure-resistant cells did not contain P1. Mice immunized with two 25-micrograms injections of LPSI produced antibodies against LPSI and phase I whole cells. No antibody was detected against phase II whole cells. Immunization with P1 induced antibody against the LPSI fraction and phase I and phase II whole cells. P1 was more effective than LPSI in reducing the number of infectious C. burnetii in the spleens of challenged mice. The gene encoding another protein (P2) recognized by P1 monoclonal antibodies was cloned and sequenced.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2378463     DOI: 10.1111/j.1749-6632.1990.tb42243.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  21 in total

1.  Cloning and porin activity of the major outer membrane protein P1 from Coxiella burnetii.

Authors:  Sunita Varghees; Kati Kiss; Giovanni Frans; Orit Braha; James E Samuel
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

2.  A Coxiella burnetti repeated DNA element resembling a bacterial insertion sequence.

Authors:  T A Hoover; M H Vodkin; J C Williams
Journal:  J Bacteriol       Date:  1992-09       Impact factor: 3.490

3.  Comparison of a commercial enzyme-linked immunosorbent assay with immunofluorescence and complement fixation tests for detection of Coxiella burnetii (Q fever) immunoglobulin M.

Authors:  P R Field; J L Mitchell; A Santiago; D J Dickeson; S W Chan; D W Ho; A M Murphy; A J Cuzzubbo; P L Devine
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

4.  Immunological response to the Brucella abortus GroEL homolog.

Authors:  J Lin; L G Adams; T A Ficht
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

5.  Development of a lipopolysaccharide-targeted peptide mimic vaccine against Q fever.

Authors:  Ying Peng; Yan Zhang; William J Mitchell; Guoquan Zhang
Journal:  J Immunol       Date:  2012-10-10       Impact factor: 5.422

6.  Genome-wide profiling of humoral immune response to Coxiella burnetii infection by protein microarray.

Authors:  Adam Vigil; Rocio Ortega; Rie Nakajima-Sasaki; Jozelyn Pablo; Douglas M Molina; Chien-Chung Chao; Hua-Wei Chen; Wei-Mei Ching; Philip L Felgner
Journal:  Proteomics       Date:  2010-06       Impact factor: 3.984

Review 7.  Adaptive immunity to the obligate intracellular pathogen Coxiella burnetii.

Authors:  Jeffrey G Shannon; Robert A Heinzen
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

8.  Combined vaccination of live 1B Chlamydophila abortus and killed phase I Coxiella burnetii vaccine does not destroy protection against chlamydiosis in a mouse model.

Authors:  Abdessalem Rekiki; Amel Bouakane; Annie Rodolakis
Journal:  Can J Vet Res       Date:  2004-07       Impact factor: 1.310

Review 9.  Control of rickettsial diseases.

Authors:  J Kazár; R Brezina
Journal:  Eur J Epidemiol       Date:  1991-05       Impact factor: 8.082

10.  Low-dose priming before vaccination with the phase I chloroform-methanol residue vaccine against Q fever enhances humoral and cellular immune responses to Coxiella burnetii.

Authors:  David M Waag; Marilyn J England; Christopher R Bolt; Jim C Williams
Journal:  Clin Vaccine Immunol       Date:  2008-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.